Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23569455 | 0.86 | GABRA1 (0.32) | GABRA1GABRB1 | |
| SCHEMBL23569063 | 0.86 | MEN1 (0.33) | TSHRMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL23969729 | 0.86 | GABRA1 (0.32) | GABRA1GABRB1 | |
| SCHEMBL24462729 | 0.83 | GABRA1 (0.30) | GABRA1GABRB1 | |
| SCHEMBL23569041 | 0.82 | GABRA1 (0.32) | GABRA1GABRB1 | |
| SCHEMBL23569058 | 0.82 | GABRA1 (0.32) | GABRA1GABRB1 | |
| SCHEMBL23569062 | 0.82 | TSHR (0.39) | TSHRMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL23569142 | 0.82 | TSHR (0.39) | TSHRMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL23569135 | 0.82 | LMNA (0.33) | TSHRMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL23569132 | 0.80 | TSHR (0.47) | TSHRMEN1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787811-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11161847-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20210300920-A1 | KRAS Mutant Protein Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2021-09-30 | — | — | US | disclosed |
| WO-2021121367-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300920-A1 | KRAS Mutant Protein Inhibitors | KRAS, NRAS, APC | TSHR 4145/4885MEN1 1089/4885ALDH1A1 3827/4885 |
| US-11161847-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | TSHR 4145/4885MEN1 1089/4885ALDH1A1 3827/4885 |
| US-11787811-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | TSHR 4270/4885MEN1 1118/4885ALDH1A1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.